Erlot 150mg Tablet

About

Erlotinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used in the treatment of certain types of cancer. It works by blocking the activity of the EGFR protein, which is often overexpressed or mutated in cancer cells, thereby inhibiting cell growth and proliferation. This targeted therapy is particularly effective in patients with non-small cell lung cancer (NSCLC) who have specific EGFR mutations, as identified by diagnostic testing. It can also be used in combination with other agents for pancreatic cancer.

The drug interferes with signaling pathways crucial for tumor development and progression, offering a more specific approach compared to traditional chemotherapy. Its mechanism helps to slow or stop the growth of cancer cells, improving patient outcomes in selected populations and providing a valuable option for advanced disease management.

Uses

• Non-small cell lung cancer (NSCLC) with specific EGFR mutations.
• Maintenance therapy for advanced NSCLC.
• Pancreatic cancer in combination with gemcitabine.
• Second-line treatment for advanced NSCLC after failure of prior chemotherapy.

Directions For Use

Take this tablet orally once daily, preferably on an empty stomach, at least one hour before or two hours after food. Follow your doctor's prescribed dosage and duration.

Benefits

• Targets specific cancer pathways.
• Effective in EGFR-mutated NSCLC.
• Oral administration for convenience.
• May improve progression-free survival.
• Offers a targeted therapy option.
• Can be used as monotherapy or in combination.

Side Effects

• Skin rash
• Diarrhea
• Nausea
• Vomiting
• Fatigue
• Anorexia
• Dry skin
• Conjunctivitis
• Stomatitis
• Interstitial lung disease (rare)
• Liver enzyme elevation
• Peripheral neuropathy

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may exacerbate liver side effects or interact with the medication.
• Pregnancy - Erlotinib is contraindicated in pregnancy due to potential fetal harm. Effective contraception is required during treatment and for a period after.
• Breastfeeding - Breastfeeding is not recommended during treatment with Erlotinib and for at least 2 weeks after the last dose, due to potential harm to the infant.
• Liver - Use with caution in patients with hepatic impairment; dose adjustments may be necessary. Regular liver function monitoring is crucial.
• Kidney - Use with caution in patients with severe renal impairment. No specific dose adjustment is typically required for mild to moderate impairment.
• Lung - Monitor for new or worsening pulmonary symptoms, as interstitial lung disease (ILD) is a rare but serious side effect. Discontinue if ILD is suspected.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.